Inferra AIResearch Tools

Inferra AI / Company / BLTE

Belite Bio, Inc.

BLTE · Health Care

Last earnings Aug 13, 2026

AI analysis

Q2 2025 · reported Aug 11, 2025

Based on: Earnings release (6-K exhibit) + parent 6-K — transcript not held

No extracted figures held

The event-summary record for this company carries no extracted figures, so the brief and charts cannot be drawn yet. The summary below and the held documents are the record for this event.

Guidance · company-stated

No guidance located in the held release

Next earningsNo verified date on fileNo date is estimated or imported
General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

Belite Bio Reports Second Quarter 2025 Financial Results and Provides a Corporate Update · Tinlarebant granted Breakthrough Therapy Designation for Stargardt disease (STGD1) by the U.S

Based on: Earnings release (6-K exhibit) + parent 6-K — transcript not held

Guidance & outlook

No guidance located in the held release

Strategy & priorities

ET SAN DIEGO, August 11, 2025- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced its financial results for the second quarter ended June 30, 2025, and provided a general business update.

SEC original ↗Belite Bio, Inc. — Earnings release (6-K exhibit)EX-99Aug 11, 2025

“This quarter, we remained on track with the strategic objectives we outlined at the start of the year, including the completion of enrollment in our pivotal Phase 3 PHOENIX trial — an important milestone in our development efforts for people living with geographic atrophy,” said Dr.

SEC original ↗Belite Bio, Inc. — Earnings release (6-K exhibit)EX-99Aug 11, 2025

With the DRAGON trial on track to complete by the end of this year, we remain focused on advancing Tinlarebant toward key clinical and regulatory milestones.

SEC original ↗Belite Bio, Inc. — Earnings release (6-K exhibit)EX-99Aug 11, 2025

About Belite Bio Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical need, such as Stargardt disease type 1 (STGD1) and Geographic Atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases.

SEC original ↗Belite Bio, Inc. — Earnings release (6-K exhibit)EX-99Aug 11, 2025

Documents

Earnings deck slides

0 decks with slide view

Belite Bio, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Belite Bio, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Belite Bio, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Competitors

Competitors & peers

Same GICS sector — classification peers, not declared competitors

Gilead Sciences (GILD) Health CareGenmab (GMAB) Health CareAlcon (ALC) Health CareArgenx (ARGX) Health CareSanofi (SNY) Health CareMerck & Co. (MRK) Health CareXencor Inc (XNCR) Health CareIllumina, Inc. (ILMN) Health Care

Filings

55 documents

Earnings releases

9 documents

Presentations

3 documents

Transcripts

0 documents

No transcripts for Belite Bio, Inc. are held in this edition of the library.

See also the earnings calendar for every tracked company’s next earnings date.